{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:07:28Z","timestamp":1790676448456,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ebiom.2022.103950","type":"journal-article","created":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T11:28:05Z","timestamp":1648294085000},"page":"103950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Indirubin-3\u2019-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma"],"prefix":"10.1016","volume":"78","author":[{"given":"Zhen","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaozhong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fancui","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengteng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.ebiom.2022.103950_bib0071","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-16-0868","article-title":"Immune Therapies in Multiple Myeloma","volume":"22","author":"Kumar","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ebiom.2022.103950_bib0072","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41375-019-0590-x","article-title":"Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma","volume":"34","author":"An","year":"2020","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.ebiom.2022.103950_bib0001","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1038\/s41388-019-0675-z","article-title":"Proteasome inhibition boosts autophagic degradation of ubiquitinated-AGR2 and enhances the antitumor efficiency of bevacizumab","volume":"38","author":"Wang","year":"2019","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.ebiom.2022.103950_bib0002","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/sj.cdd.4401702","article-title":"The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle","volume":"12","author":"Hershko","year":"2005","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.ebiom.2022.103950_bib0003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0305-7372(03)00081-1","article-title":"The proteasome: structure, function, and role in the cell","volume":"29","author":"Adams","year":"2003","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"10.1016\/j.ebiom.2022.103950_bib0004","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrc1994","article-title":"Ubiquitin and ubiquitin-like proteins in cancer pathogenesis","volume":"6","author":"Hoeller","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"10.1016\/j.ebiom.2022.103950_bib0005","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1172\/JCI98765","article-title":"Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma","volume":"128","author":"Franqui-Machin","year":"2018","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.ebiom.2022.103950_bib0006","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","article-title":"A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance","volume":"22","author":"Chauhan","year":"2012","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.ebiom.2022.103950_bib0007","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.ebiom.2022.103950_bib0008","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1182\/blood-2018-11-877795","article-title":"Introduction to a review series on advances in multiple myeloma","volume":"133","author":"Avet-Loiseau","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ebiom.2022.103950_bib0009","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.ebiom.2022.103950_bib0010","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1053\/j.seminhematol.2012.04.006","article-title":"Biologic impact of proteasome inhibition in multiple myeloma cells\u2013from the aspects of preclinical studies","volume":"49","author":"Hideshima","year":"2012","journal-title":"Semin Hematol"},{"issue":"13","key":"10.1016\/j.ebiom.2022.103950_bib0011","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1182\/blood-2008-08-172734","article-title":"The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition","volume":"113","author":"Bianchi","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ebiom.2022.103950_bib0012","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2016.325","article-title":"Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma","volume":"31","author":"Qin","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ebiom.2022.103950_bib0013","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.drup.2014.12.001","article-title":"Molecular basis of resistance to proteasome inhibitors in hematological malignancies","volume":"18","author":"Niewerth","year":"2015","journal-title":"Drug Resist Updat"},{"issue":"2","key":"10.1016\/j.ebiom.2022.103950_bib0014","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41375-018-0216-8","article-title":"Spectrum and functional validation of PSMB5 mutations in multiple myeloma","volume":"33","author":"Barrio","year":"2019","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.ebiom.2022.103950_bib0015","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/leu.2016.97","article-title":"Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma","volume":"30","author":"Song","year":"2016","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.ebiom.2022.103950_bib0016","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.3109\/10428194.2011.576791","article-title":"Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression","volume":"52","author":"Hao","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ebiom.2022.103950_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107526","article-title":"Exploring the proteasome system: A novel concept of proteasome inhibition and regulation","volume":"211","author":"Wang","year":"2020","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ebiom.2022.103950_bib0018","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41375-020-0865-2","article-title":"Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13","volume":"35","author":"Du","year":"2021","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ebiom.2022.103950_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/biom11020228","article-title":"PA28gamma: new insights on an ancient proteasome activator","volume":"11","author":"Cascio","year":"2021","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.ebiom.2022.103950_bib0020","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/cdd.2014.188","article-title":"Regulation of c-Myc protein stability by proteasome activator REGgamma","volume":"22","author":"Li","year":"2015","journal-title":"Cell Death Differ"},{"issue":"1","key":"10.1016\/j.ebiom.2022.103950_bib0021","doi-asserted-by":"crossref","first-page":"15224","DOI":"10.1038\/s41598-019-51665-0","article-title":"Proteasome activator PA200 regulates myofibroblast differentiation","volume":"9","author":"Welk","year":"2019","journal-title":"Sci Rep"},{"issue":"15","key":"10.1016\/j.ebiom.2022.103950_bib0022","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.7150\/thno.18345","article-title":"Preclinical activity of DCZ3301, a novel aryl-guanidino compound in the therapy of multiple myeloma","volume":"7","author":"Gao","year":"2017","journal-title":"Theranostics"},{"issue":"14","key":"10.1016\/j.ebiom.2022.103950_bib0023","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1182\/blood-2018-06-859686","article-title":"Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma","volume":"133","author":"Zhuang","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ebiom.2022.103950_bib0024","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.canlet.2015.06.011","article-title":"Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma","volume":"366","author":"Zang","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ebiom.2022.103950_bib0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ebiom.2017.02.011","article-title":"Multiple myeloma tumor cells are selectively killed by pharmacologically-dosed ascorbic acid","volume":"18","author":"Xia","year":"2017","journal-title":"EBioMedicine"},{"issue":"7","key":"10.1016\/j.ebiom.2022.103950_bib0026","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/1541-7786.MCR-19-0852","article-title":"Polycomb-like protein 3 induces proliferation and drug resistance in multiple myeloma and is regulated by miRNA-15a","volume":"18","author":"Yu","year":"2020","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ebiom.2022.103950_bib0027","doi-asserted-by":"crossref","DOI":"10.1038\/s41417-020-0161-3","article-title":"Therapeutic effects of oligo-single-stranded DNA mimicking of hsa-miR-15a-5p on multiple myeloma","author":"Li","year":"2020","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"10.1016\/j.ebiom.2022.103950_bib0028","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1158\/0008-5472.CAN-15-1926","article-title":"Cancer cell dissemination and homing to the bone marrow in a zebrafish model","volume":"76","author":"Sacco","year":"2016","journal-title":"Cancer Res"},{"issue":"7671","key":"10.1016\/j.ebiom.2022.103950_bib0029","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nature23883","article-title":"m(6)A modulates haematopoietic stem and progenitor cell specification","volume":"549","author":"Zhang","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ebiom.2022.103950_bib0030","doi-asserted-by":"crossref","first-page":"20508","DOI":"10.1038\/s41598-020-77450-y","article-title":"Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment","volume":"10","author":"Liu","year":"2020","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.ebiom.2022.103950_bib0031","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J Comput Chem"},{"issue":"W1","key":"10.1016\/j.ebiom.2022.103950_bib0032","doi-asserted-by":"crossref","first-page":"W296","DOI":"10.1093\/nar\/gky427","article-title":"SWISS-MODEL: homology modelling of protein structures and complexes","volume":"46","author":"Waterhouse","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"25","key":"10.1016\/j.ebiom.2022.103950_bib0033","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.1002\/chem.201700588","article-title":"Reversible Covalent and Supramolecular Functionalization of Water-Soluble Gold(I) Complexes","volume":"23","author":"Kemper","year":"2017","journal-title":"Chemistry"},{"issue":"4","key":"10.1016\/j.ebiom.2022.103950_bib0034","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.cub.2020.11.010","article-title":"Smoothelin-like 2 inhibits coronin-1B to stabilize the apical actin cortex during epithelial morphogenesis","volume":"31","author":"Hachimi","year":"2021","journal-title":"Curr Biol"},{"key":"10.1016\/j.ebiom.2022.103950_bib0035","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1756-8722-4-37","article-title":"Suppressing miRNA-15a\/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells","volume":"4","author":"Hao","year":"2011","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.ebiom.2022.103950_bib0036","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1182\/blood-2016-03-704460","article-title":"A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy","volume":"128","author":"Lin","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ebiom.2022.103950_bib0037","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2017.115","article-title":"NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma","volume":"31","author":"Hao","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.ebiom.2022.103950_bib0038","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.molcel.2007.05.022","article-title":"Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome","volume":"26","author":"Chen","year":"2007","journal-title":"Mol Cell"},{"issue":"25","key":"10.1016\/j.ebiom.2022.103950_bib0039","doi-asserted-by":"crossref","first-page":"13147","DOI":"10.1074\/jbc.M116.717652","article-title":"Inhibition of proteasome activity induces formation of alternative proteasome complexes","volume":"291","author":"Welk","year":"2016","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.ebiom.2022.103950_bib0040","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/9035","article-title":"Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases","volume":"1","author":"Hoessel","year":"1999","journal-title":"Nat Cell Biol"},{"issue":"9","key":"10.1016\/j.ebiom.2022.103950_bib0041","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1080\/1042819021000006295","article-title":"Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China","volume":"43","author":"Xiao","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.ebiom.2022.103950_bib0042","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.leukres.2005.05.012","article-title":"Anti-angiogenesis effects of meisoindigo on chronic myelogenous leukemia in vitro","volume":"30","author":"Xiao","year":"2006","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.ebiom.2022.103950_bib0043","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/cvr\/cvt339","article-title":"Indirubin-3\u2032-monoxime exerts a dual mode of inhibition towards leukotriene-mediated vascular smooth muscle cell migration","volume":"101","author":"Blazevic","year":"2014","journal-title":"Cardiovasc Res"},{"issue":"5","key":"10.1016\/j.ebiom.2022.103950_bib0044","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.3892\/or.2013.2334","article-title":"Indirubin-3\u2032-monoxime promotes autophagic and apoptotic death in JM1 human acute lymphoblastic leukemia cells and K562 human chronic myelogenous leukemia cells","volume":"29","author":"Lee","year":"2013","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ebiom.2022.103950_bib0045","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.1c01311","article-title":"Indirubin derivatives as dual inhibitors targeting cyclin-dependent kinase and histone deacetylase for treating cancer","author":"Cao","year":"2021","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.ebiom.2022.103950_bib0046","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.chembiol.2012.09.008","article-title":"Indirubin derivatives modulate TGF\u03b2\/BMP signaling at different levels and trigger ubiquitin-mediated depletion of nonactivated R-Smads","volume":"19","author":"Cheng","year":"2012","journal-title":"Chem Biol"},{"issue":"1","key":"10.1016\/j.ebiom.2022.103950_bib0047","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202012097","article-title":"pVHL-mediated SMAD3 degradation suppresses TGF-beta signaling","volume":"221","author":"Zhou","year":"2022","journal-title":"J Cell Biol"},{"issue":"5","key":"10.1016\/j.ebiom.2022.103950_bib0048","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ccell.2016.03.026","article-title":"Tight junction protein 1 modulates proteasome capacity and proteasome inhibitor sensitivity in multiple myeloma via EGFR\/JAK1\/STAT3 signaling","volume":"29","author":"Zhang","year":"2016","journal-title":"Cancer Cell"},{"issue":"7677","key":"10.1016\/j.ebiom.2022.103950_bib0049","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature24451","article-title":"Molecular basis of USP7 inhibition by selective small-molecule inhibitors","volume":"550","author":"Turnbull","year":"2017","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ebiom.2022.103950_bib0050","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nsmb1067","article-title":"Molecular recognition of p53 and MDM2 by USP7\/HAUSP","volume":"13","author":"Sheng","year":"2006","journal-title":"Nat Struct Mol Biol"},{"issue":"10","key":"10.1016\/j.ebiom.2022.103950_bib0051","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/nm.4180","article-title":"HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma","volume":"22","author":"Tavana","year":"2016","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ebiom.2022.103950_bib0052","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1038\/s41598-020-62076-x","article-title":"Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism","volume":"10","author":"Schauer","year":"2020","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.ebiom.2022.103950_bib0053","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2007.09.007","article-title":"Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation","volume":"12","author":"Itahana","year":"2007","journal-title":"Cancer Cell"},{"issue":"6982","key":"10.1016\/j.ebiom.2022.103950_bib0054","doi-asserted-by":"crossref","DOI":"10.1038\/nature02501","article-title":"Tumour suppression: disruption of HAUSP gene stabilizes p53","volume":"428","author":"Cummins","year":"2004","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ebiom.2022.103950_bib0055","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/onc.2009.427","article-title":"Inactivation of HAUSP in vivo modulates p53 function","volume":"29","author":"Kon","year":"2010","journal-title":"Oncogene"},{"issue":"16","key":"10.1016\/j.ebiom.2022.103950_bib0056","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1111\/j.1742-4658.2007.05952.x","article-title":"Biochemical characterization of USP7 reveals post-translational modification sites and structural requirements for substrate processing and subcellular localization","volume":"274","author":"Fern\u00e1ndez-Montalv\u00e1n","year":"2007","journal-title":"Febs J"},{"issue":"21","key":"10.1016\/j.ebiom.2022.103950_bib0057","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1016\/j.febslet.2011.09.040","article-title":"Structural variability of the ubiquitin specific protease DUSP-UBL double domains","volume":"585","author":"Elliott","year":"2011","journal-title":"FEBS Lett"},{"issue":"5","key":"10.1016\/j.ebiom.2022.103950_bib0058","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cell.2017.04.023","article-title":"The logic of the 26S proteasome","volume":"169","author":"Collins","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2022.103950_bib0059","first-page":"237","article-title":"Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma","volume":"5","author":"Fostier","year":"2012","journal-title":"Onco Targets Ther"},{"issue":"12","key":"10.1016\/j.ebiom.2022.103950_bib0060","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41408-020-00393-0","article-title":"Downregulation of PA28\u03b1 induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma","volume":"10","author":"Gu","year":"2020","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.ebiom.2022.103950_bib0061","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/leu.2014.279","article-title":"MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib","volume":"29","author":"Jagannathan","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ebiom.2022.103950_bib0062","doi-asserted-by":"crossref","DOI":"10.3390\/biom11020228","article-title":"PA28\u03b3: new insights on an ancient proteasome activator","volume":"11","author":"Cascio","year":"2021","journal-title":"Biomolecules."},{"issue":"6","key":"10.1016\/j.ebiom.2022.103950_bib0063","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/emboj.2008.25","article-title":"Proteasome activator PA28 gamma regulates p53 by enhancing its MDM2-mediated degradation","volume":"27","author":"Zhang","year":"2008","journal-title":"EMBO J"},{"key":"10.1016\/j.ebiom.2022.103950_bib0064","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.canlet.2016.08.018","article-title":"Proteasome activator subunit 3 promotes pancreatic cancer growth via c-Myc-glycolysis signaling axis","volume":"386","author":"Guo","year":"2017","journal-title":"Cancer Lett"},{"issue":"6","key":"10.1016\/j.ebiom.2022.103950_bib0065","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41375-018-0036-x","article-title":"Targeting MYC in multiple myeloma","volume":"32","author":"Jovanovic","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.ebiom.2022.103950_bib0066","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1761205","article-title":"Tumors escape immunosurveillance by overexpressing the proteasome activator PSME3","volume":"9","author":"Boulpicante","year":"2020","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.ebiom.2022.103950_bib0067","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.yexcr.2017.05.017","article-title":"PSME3 induces epithelial-mesenchymal transition with inducing the expression of CSC markers and immunosuppression in breast cancer","volume":"358","author":"Yi","year":"2017","journal-title":"Exp Cell Res"},{"issue":"5","key":"10.1016\/j.ebiom.2022.103950_bib0068","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molcel.2010.02.002","article-title":"Structure of a Blm10 complex reveals common mechanisms for proteasome binding and gate opening","volume":"37","author":"Sadre-Bazzaz","year":"2010","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.ebiom.2022.103950_bib0069","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.molcel.2019.07.014","article-title":"Characterization of fully recombinant human 20S and 20S-PA200 proteasome complexes","volume":"76","author":"Toste R\u00eago","year":"2019","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.ebiom.2022.103950_bib0070","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ccr.2012.12.001","article-title":"NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers","volume":"23","author":"Zhou","year":"2013","journal-title":"Cancer Cell"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422001347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422001347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:16:05Z","timestamp":1762456565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396422001347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":72,"alternative-id":["S2352396422001347"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.103950","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Indirubin-3\u2019-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.103950","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103950"}}